Genentech’s Actimmune
Executive Summary
PLA filed for the gamma interferon product on Dec. 20 for the treatment of chronic granulomatous disease (CGD), an orphan disease that affects about 250 patients in the U.S. The PLA includes data from 128 patients. Actimmune is also in Phase III trials for the treatment of infections in patients with traumatic injuries and as an adjuvant therapy in the treatment of patients with melanoma and small cell lung cancer. Other companies with gamma interferons in development include Biogen, Amgen and Chiron.
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.